Krystal Biotech (NASDAQ:KRYS) had its target price hoisted by HC Wainwright from $32.00 to $35.50 in a research report report published on Monday, The Fly reports. They currently have a buy rating on the stock.
A number of other equities analysts have also recently weighed in on KRYS. Zacks Investment Research cut Krystal Biotech from a buy rating to a hold rating in a research note on Saturday, September 1st. Cantor Fitzgerald reissued a buy rating and issued a $35.00 price target on shares of Krystal Biotech in a research note on Monday. ValuEngine raised Krystal Biotech from a hold rating to a buy rating in a research note on Friday, September 21st. LADENBURG THALM/SH SH set a $38.00 price target on Krystal Biotech and gave the stock a buy rating in a research note on Thursday, July 19th. Finally, William Blair started coverage on Krystal Biotech in a research note on Monday, August 6th. They issued a buy rating on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $32.30.
NASDAQ:KRYS opened at $22.25 on Monday. The stock has a market cap of $235.06 million and a P/E ratio of -13.96. Krystal Biotech has a 52-week low of $8.03 and a 52-week high of $24.89.
An institutional investor recently raised its position in Krystal Biotech stock. Acadian Asset Management LLC boosted its holdings in shares of Krystal Biotech Inc (NASDAQ:KRYS) by 552.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,202 shares of the company’s stock after acquiring an additional 10,331 shares during the quarter. Acadian Asset Management LLC owned 0.12% of Krystal Biotech worth $182,000 at the end of the most recent quarter. 21.77% of the stock is currently owned by institutional investors and hedge funds.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
See Also: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.